The role of glycogen synthase kinase 3-β in immunity and cell cycle: Implications in esophageal cancer

Archivum Immunologiae et Therapiae Experimentalis

Volumn 62, Issue 2, 2014, Pages 131-144

  Gao, Shegan ^a   Brown, Jonathan ^b   Wang, Huizhi ^c   Feng, Xiaoshan ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

Esophageal cancer; GSK3; Inflammation; Inflammatory cytokines; PI3K

Indexed keywords

BETA CATENIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN C JUN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1;

CANCER GROWTH; CANCER PROGNOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; ESOPHAGUS CANCER; GLUCOSE METABOLISM; HUMAN; IMMUNITY; INFLAMMATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNITY; TRANSCRIPTION FACTORS;

EID: 84896546981     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-013-0263-9     Document Type: Review

References (176)

1. Abdel-Latif MM, O'Riordan J, Windle HJ et al (2004) NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 239:491-500
2. Abdel-Latif MM, Kelleher D, Reynolds JV (2009) Potential role of NF-kappaB in esophageal adenocarcinoma: as an emerging molecular target. J Surg Res 153:172-180
3. Agarwal D, Dange RB, Raizada MK et al (2013) Angiotensin II causes imbalance between pro- and anti-inflammatory cytokines by modulating GSK-3beta in neuronal culture. Br J Pharmacol 169:860-874
4. Ali A, Hoeflich KP, Woodgett JR (2001) Glycogen synthase kinase-3: properties, functions, and regulation. Chem Rev 101:2527-2540
5. Arber N, Gammon MD, Hibshoosh H et al (1999) Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum Pathol 30:1087-1092
6. Arlt A, Vorndamm J, Muerkoster S et al (2002) Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 62:910-916
7. Arnott CH, Scott KA, Moore RJ et al (2002) Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1- dependent pathway. Oncogene 21:4728-4738
8. Bahl R, Arora S, Nath N et al (2000) Novel polymorphism in p21(waf1/cip1) cyclin dependent kinase inhibitor gene: association with human esophageal cancer. Oncogene 19:323-328
9. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539-545
10. Ban JO, Kwak DH, Oh JH et al (2010) Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem Biol Interact 188:75-85
11. Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8:33-40
12. Belkhiri A, Dar AA, Zaika A et al (2008) t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism. Cancer Res 68:395-403
13. Benchetrit F, Ciree A, Vives V et al (2002) Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99:2114-2121
14. Beurel E, Jope RS (2008) Differential regulation of STAT family members by glycogen synthase kinase-3. J Biol Chem 283:21934-21944
15. Beurel E, Yeh WI, Michalek SM et al (2010) Glycogen synthase kinase-3 is an early determinant in the differentiation of pathogenic Th17 cells. J Immunol 186:1391-1398
16. Blot WJ, Devesa SS, Kneller RW et al (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287-1289
17. Bornschein J, Selgrad M, Warnecke M et al (2010) H. pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci 55:3124-3131
18. Brady MJ, Bourbonais FJ, Saltiel AR (1998) The activation of glycogen synthase by insulin switches from kinase inhibition to phosphatase activation during adipogenesis in 3T3-L1 cells. J Biol Chem 273:14063-14066
19. Brierley MM, Fish EN (2005) Stats: multifaceted regulators of transcription. J Interferon Cytokine Res 25:733-744
20. Buss H, Dorrie A, Schmitz ML et al (2004) Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J Biol Chem 279:49571-49574
21. Cadigan KM, Liu YI (2006) Wnt signaling: complexity at the surface. J Cell Sci 119:395-402
22. Cao Q, Lu X, Feng YJ (2006) Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res 16:671-677
23. Cardenes M, Angel-Moreno A, Fieschi C et al (2010) Oesophageal squamous cell carcinoma in a young adult with IL-12R beta 1 deficiency. J Med Genet 47:635-637
24. Chatzopoulos D, Kyrgidis A, Kountouras J et al (2007) Bax upregulation may provide a rationale for the low incidence of esophageal adenocarcinoma in a Greek cohort of patients with Barrett's esophagus. Hepatogastroenterology 54:705-709
25. Chen D, Hu Q, Mao C et al (2012a) Increased IL-17-producing CD4(+) T cells in patients with esophageal cancer. Cell Immunol 272:166-174
26. Chen MF, Lu MS, Chen PT et al (2012b) Role of interleukin 1 beta in esophageal squamous cell carcinoma. J Mol Med 90:89-100
27. Cheng N, Chen J (2001) Tumor necrosis factor-alpha induction of endothelial ephrin A1 expression is mediated by a p38 MAPK-and SAPK/JNK-dependent but nuclear factor-kappa B-independent mechanism. J Biol Chem 276:13771-13777
28. Coleman MP, Gatta G, Verdecchia A et al (2003) EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 14(Suppl 5):v128-v149
29. Colotta F, Allavena P, Sica A et al (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073-1081
30. Crew KD, Neugut AI (2004) Epidemiology of upper gastrointestinal malignancies. Semin Oncol 31:450-464
31. Cross DA, Alessi DR, Vandenheede JR et al (1994) The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. Biochem J 303(Pt 1):21-26
32. De Cesaris P, Starace D, Starace G et al (1999) Activation of Jun N-terminal kinase/stress-activated protein kinase pathway by tumor necrosis factor alpha leads to intercellular adhesion molecule-1 expression. J Biol Chem 274:28978-28982
33. Deans DA, Wigmore SJ, Gilmour H et al (2006) Elevated tumour interleukin-1beta is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 95:1568-1575
34. Deng J, Miller SA, Wang HY et al (2002) beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2:323-334
35. Dhar A, Young MR, Colburn NH (2002) The role of AP-1, NF-kappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive. Mol Cell Biochem 234-235:185-193
36. Diakowska D, Markocka-Maczka K, Grabowski K et al (2006) Serum interleukin-12 and interleukin-18 levels in patients with oesophageal squamous cell carcinoma. Exp Oncol 28:319-322
37. Dinarello CA (2011) A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol 41:1203-1217
38. Doble BW, Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116:1175-1186
39. Eggermont AM, de Wilt JH, ten Hagen TL (2003) Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 4:429-437
40. Ellis FH Jr, Xu X, Kulke MH et al (2001) Malignant transformation of the esophageal mucosa is enhanced in p27 knockout mice. J Thorac Cardiovasc Surg 122:809-814
41. Embi N, Rylatt DB, Cohen P (1980) Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107:519-527
42. Eom TY, Jope RS (2009) GSK3 beta N-terminus binding to p53 promotes its acetylation. Mol Cancer 8:14
43. Ernst PB, Gold BD (2000) The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 54:615-640
44. Eslick GD (2010) Infectious causes of esophageal cancer. Infect Dis Clin North Am 24:845-852, vii
45. Fang X, Yu S, Tanyi JL et al (2002) Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22:2099-2110
46. Ferrajoli A, Keating MJ, Manshouri T et al (2002) The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 100:1215-1219
47. Fiol CJ, Mahrenholz AM, Wang Y et al (1987) Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J Biol Chem 262:14042-14048
48. Fitzgerald RC, Abdalla S, Onwuegbusi BA et al (2002a) Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 51:316-322
49. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M et al (2002b) Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 50:451-459
50. Frame S, Cohen P, Biondi RM (2001) A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7:1321-1327
51. Furihata M, Ishikawa T, Inoue A et al (1996) Determination of the prognostic significance of unscheduled cyclin A overexpression in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2:1781-1785
52. Garcea G, Manson MM, Neal CP et al (2007) Glycogen synthase kinase-3 beta; a new target in pancreatic cancer? Curr Cancer Drug Targets 7:209-215
53. Garcia CA, Benakanakere MR, Alard P et al (2008) Antigenic experience dictates functional role of glycogen synthase kinase-3 in human CD4? T cell responses. J Immunol 181:8363-8371
54. Garcia CA, Wang H, Benakanakere MR et al (2009) c-jun controls the ability of IL-12 to induce IL-10 production from human memory CD4? T cells. J Immunol 183:4475-4482
55. Ghiringhelli F, Apetoh L, Tesniere A et al (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15:1170-1178
56. Ghosh JC, Altieri DC (2005) Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells. Clin Cancer Res 11:4580-4588
57. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883-899
58. Grzesiak JJ, Smith KC, Chalberg C et al (2005) Type I collagen and divalent cation shifts disrupt cell-cell adhesion, increase migration, and decrease PTHrP, IL-6, and IL-8 expression in pancreatic cancer cells. Int J Gastrointest Cancer 36:131-146
59. Gupta VK, Park JO, Kurihara T et al (2003) Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model. Gene Ther 10:206-212
60. Halm U, Tannapfel A, Breitung B et al (2000) Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus. Hepatogastroenterology 47:962-966
61. Hanemaaijer R, Koolwijk P, le Clercq L et al (1993) Regulation of matrix metalloproteinase expression in human vein and micro-vascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J 296 (Pt 3):803-809
62. Harrington LE, Hatton RD, Mangan PR et al (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6:1123-1132
63. Hirano T, Nakajima K, Hibi M (1997) Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev 8:241-252
64. Ho WC, Pikor L, Gao Y et al (2012) Calpain 2 regulates Akt-FoxO-p27(Kip1) protein signaling pathway in mammary carcinoma. J Biol Chem 287:15458-15465
65. Hodge DR, Hurt EM, Farrar WL (2005) The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41:2502-2512
66. Honorati MC, Neri S, Cattini L et al (2006) Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage 14:345-352
67. Huang SP, Wu MS, Wang HP et al (2002) Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma. J Gastroenterol Hepatol 17:1165-1169
68. Hussain SP, Harris CC (2007) Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121:2373-2380
69. Hussain S, Bharti AC, Salam I et al (2009) Transcription factor AP-1 in esophageal squamous cell carcinoma: alterations in activity and expression during human Papillomavirus infection. BMC Cancer 9:329
70. Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7-G17
71. Jiang W, Kahn SM, Tomita N et al (1992) Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 52:2980-2983
72. Jimeno A, Kulesza P, Kincaid E et al (2006) C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res 66:2385-2390
73. Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29:95-102
74. Jope RS, Yuskaitis CJ, Beurel E (2007) Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32:577-595
75. Kang SY, Han JH, Lee KJ et al (2007) Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res 13:4146-4153
76. Kang T, Wei Y, Honaker Y et al (2008) GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 13:36-47
77. Kehlen A, Thiele K, Riemann D et al (1999) Interleukin-17 stimulates the expression of IkappaB alpha mRNA and the secretion of IL-6 and IL-8 in glioblastoma cell lines. J Neuroimmunol 101:1-6
78. Kito T, Kuroda E, Yokota A et al (2003) Cytotoxicity in glioma cells due to interleukin-12 and interleukin-18-stimulated macrophages mediated by interferon-gamma-regulated nitric oxide. J Neurosurg 98:385-392
79. Kockeritz L, Doble B, Patel S et al (2006) Glycogen synthase kinase- 3 - an overview of an over-achieving protein kinase. Curr Drug Targets 7:1377-1388
80. Konturek PC, Nikiforuk A, Kania J et al (2004) Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. Dig Dis Sci 49:1075-1083
81. Krelin Y, Voronov E, Dotan S et al (2007) Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 67:1062-1071
82. Kryczek I, Wei S, Szeliga W et al (2009) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114:357-359
83. Kundu JK, Surh YJ (2008) Inflammation: gearing the journey to cancer. Mutat Res 659:15-30
84. Kuwahara M, Hirai T, Yoshida K et al (1999) p53, p21(Waf1/Cip1) and cyclin D1 protein expression and prognosis in esophageal cancer. Dis Esophagus 12:116-119
85. Leu CM, Wong FH, Chang C et al (2003) Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 22:7809-7818
86. Li P, Nijhawan D, Budihardjo I et al (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479-489
87. Li N, Grivennikov SI, Karin M (2011) The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 19:429-431
88. Lv L, Pan K, Li XD et al (2011) The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS ONE 6:e18219
89. Ma X, Chow JM, Gri G et al (1996) The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med 183:147-157
90. Ma Y, Wang M, Li N et al (2009) Bleomycin-induced nuclear factor-kappaB activation in human bronchial epithelial cells involves the phosphorylation of glycogen synthase kinase 3beta. Toxicol Lett 187:194-200
91. Ma Y, Aymeric L, Locher C et al (2011) Contribution of IL-17- producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 208:491-503
92. Mai W, Kawakami K, Shakoori A et al (2009) Deregulated GSK3{beta} sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase. Clin Cancer Res 15:6810-6819
93. Maihofner C, Charalambous MP, Bhambra U et al (2003) Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer. Carcinogenesis 24:665-671
94. Maritz MF, van der Watt PJ, Holderness N et al (2011) Inhibition of AP-1 suppresses cervical cancer cell proliferation and is associated with p21 expression. Biol Chem 392:439-448
95. Martin M, Rehani K, Jope RS et al (2005) Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6:777-784
96. Masuhara M, Sakamoto H, Matsumoto A et al (1997) Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun 239:439-446
97. Matsumoto M, Furihata M, Ishikawa T et al (1999) Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma. Br J Cancer 80:256-261
98. Mattarollo SR, Loi S, Duret H et al (2011) Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 71:4809-4820
99. Meares GP, Mines MA, Beurel E et al (2011) Glycogen synthase kinase-3 regulates endoplasmic reticulum (ER) stress-induced CHOP expression in neuronal cells. Exp Cell Res 317:1621-1628
100. Menke V, van Zoest KP, Moons LM et al (2012) NcoI TNF-beta gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma. Scand J Gastroenterol 47:378-386
101. Moh A, Zhang W, Yu S et al (2008) STAT3 sensitizes insulin signaling by negatively regulating glycogen synthase kinase-3 beta. Diabetes 57:1227-1235
102. Moons LM, Kusters JG, van Delft JH et al (2008) A pro-inflammatory genotype predisposes to Barrett's esophagus. Carcinogenesis 29:926-931
103. Mu J, Zou JP, Yamamoto N et al (1995) Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 55:4404-4408
104. Mukai F, Ishiguro K, Sano Y et al (2002) Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J Neurochem 81:1073-1083
105. Mukhopadhyay P, Ali MA, Nandi A et al (2006) The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1beta-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells. Cancer Res 66:1758-1766
106. Murakami M, Hibi M, Nakagawa N et al (1993) IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260:1808-1810
107. Murakami H, Furihata M, Ohtsuki Y et al (1999) Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma. Virchows Arch 434:153-158
108. Nakamura T, Hayashi K, Ota M et al (2004) Expression of p21(Waf1/ Cip1) predicts response and survival of esophageal cancer patients treated by chemoradiotherapy. Dis Esophagus 17:315-321
109. Nakao T, Geddis AE, Fox NE et al (2008) PI3 K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27(Kip1). Cell Cycle 7:257-266
110. Niessen CM, Gottardi CJ (2008) Molecular components of the adherens junction. Biochim Biophys Acta 1778:562-571
111. Ohtani M, Nagai S, Kondo S et al (2008) Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood 112:635-643
112. Ohteki T, Parsons M, Zakarian A et al (2000) Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. J Exp Med 192:99-104
113. Oka M, Iizuka N, Yamamoto K et al (1996a) The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 16:1001-1006
114. Oka M, Yamamoto K, Takahashi M et al (1996b) Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 56:2776-2780
115. Ola MS, Nawaz M, Ahsan H (2011) Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem 351:41-58
116. O'Riordan JM, Abdel-latif MM, Ravi N et al (2005) Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation- metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 100:1257-1264
117. Ougolkov AV, Fernandez-Zapico ME, Bilim VN et al (2006) Aberrant nuclear accumulation of glycogen synthase kinase- 3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res 12:5074-5081
118. Ougolkov AV, Bone ND, Fernandez-Zapico ME et al (2007) Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 110:735-742
119. Pages F, Ragueneau M, Rottapel R et al (1994) Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 369:327-329
120. Park H, Li Z, Yang XO et al (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6:1133-1141
121. Patel S, Woodgett J (2008) Glycogen synthase kinase-3 and cancer: good cop, bad cop? Cancer Cell 14:351-353
122. Paweletz CP, Charboneau L, Bichsel VE et al (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20:1981-1989
123. Peyrollier K, Hajduch E, Blair AS et al (2000) L-leucine availability regulates phosphatidylinositol 3-kinase, p70 S6 kinase and glycogen synthase kinase-3 activity in L6 muscle cells: evidence for the involvement of the mammalian target of rapamycin (mTOR) pathway in the L-leucine-induced up-regulation of system A amino acid transport. Biochem J 350(Pt 2):361-368
124. Pham-Nguyen KB, Yang W, Saxena R et al (1999) Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma. Int J Cancer 81:813-819
125. Rehani K, Wang H, Garcia CA et al (2009) Toll-like receptor-mediated production of IL-1Ra is negatively regulated by GSK3 via the MAPK ERK1/2. J Immunol 182:547-553
126. Rossig L, Badorff C, Holzmann Y et al (2002) Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J Biol Chem 277:9684-9689
127. Saito T, Kato H, Saito M et al (1994a) TNF receptor number-dependent cytotoxicity to TNF-resistant human esophageal cancer cell lines by combination with recombinant human necrosis factor and hyperthermia. Hum Cell 7:55-61
128. Saito Y, Vandenheede JR, Cohen P (1994b) The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells. Biochem J 303(Pt 1):27-31
129. Sanchez JF, Sniderhan LF, Williamson AL et al (2003) Glycogen synthase kinase 3beta-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappaB signaling. Mol Cell Biol 23:4649-4662
130. Sarbia M, Bittinger F, Porschen R et al (1996) bcl-2 expression and prognosis in squamous-cell carcinomas of the esophagus. Int J Cancer 69:324-328
131. Sarbia M, Verreet P, Bittinger F et al (1997) Basaloid squamous cell carcinoma of the esophagus: diagnosis and prognosis. Cancer 79:1871-1878
132. Scully C, Bagan JV (2009) Recent advances in oral oncology 2008; squamous cell carcinoma imaging, treatment, prognostication and treatment outcomes. Oral Oncol 45:e25-e30
133. Shakoori A, Ougolkov A, Yu ZW et al (2005) Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 334:1365-1373
134. Shaw M, Cohen P (1999) Role of protein kinase B and the MAP kinase cascade in mediating the EGF-dependent inhibition of glycogen synthase kinase 3 in Swiss 3T3 cells. FEBS Lett 461:120-124
135. Sheridan CM, Heist EK, Beals CR et al (2002) Protein kinase A negatively modulates the nuclear accumulation of NF-ATc1 by priming for subsequent phosphorylation by glycogen synthase kinase-3. J Biol Chem 277:48664-48676
136. Sugimura K, Miyata H, Tanaka K et al (2012) Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res 18:5144-5153
137. Suzuki M, Shinohara F, Endo M et al (2009) Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells. Cancer Chemother Pharmacol 64:223-232
138. Taira N, Mimoto R, Kurata M et al (2012) DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells. J Clin Invest 122:859-872
139. Tan J, Zhuang L, Leong HS et al (2005) Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res 65:9012-9020
140. Thomas GM, Frame S, Goedert M et al (1999) A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin. FEBS Lett 458:247-251
141. Tong Q, Zhang W, Jin S et al (2011) The relationship between p27(kip1) expression and the change of radiosensitivity of esophageal carcinoma cells. Scand J Gastroenterol 46:173-176
142. Tselepis C, Perry I, Dawson C et al (2002) Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 21:6071-6081
143. Tsuboi K, Miyazaki T, Nakajima M et al (2004) Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma. Cancer Lett 205:207-214
144. Turkson J (2004) STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 8:409-422
145. Vallbohmer D, Lenz HJ (2006) Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 19:425-432
146. van Sandick JW, Gisbertz SS, ten Berge IJ et al (2003) Immune responses and prediction of major infection in patients undergoing transhiatal or transthoracic esophagectomy for cancer. Ann Surg 237:35-43
147. Veeramachaneni NK, Kubokura H, Lin L et al (2004) Down-regulation of beta catenin inhibits the growth of esophageal carcinoma cells. J Thorac Cardiovasc Surg 127:92-98
148. Verbeke S, Meignan S, Lagadec C et al (2010) Overexpression of p75(NTR) increases survival of breast cancer cells through p21(waf1). Cell Signal 22:1864-1873
149. Verde P, Casalino L, Talotta F et al (2007) Deciphering AP-1 function in tumorigenesis: fra-ternizing on target promoters. Cell Cycle 6:2633-2639
150. Voest EE, Kenyon BM, O'Reilly MS et al (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581-586
151. Voronov E, Shouval DS, Krelin Y et al (2003) IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100:2645-2650
152. Vujanovic NL (2001) Role of TNF family ligands in antitumor activity of natural killer cells. Int Rev Immunol 20:415-437
153. Wang QS, Sabourin CL, Wang H et al (1996) Overexpression of cyclin D1 and cyclin E in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Carcinogenesis 17:1583-1588
154. Wang LD, Zhou Q, Wei JP et al (1998) Apoptosis and its relationship with cell proliferation, p53, Waf1p21, bcl-2 and c-Myc in esophageal carcinogenesis studied with a high-risk population in northern China. World J Gastroenterol 4:287-293
155. Wang LD, Zheng S, Zheng ZY et al (2003) Primary adenocarcinomas of lower esophagus, esophagogastric junction and gastric cardia: in special reference to China. World J Gastroenterol 9:1156-1164
156. Wang H, Garcia CA, Rehani K et al (2008) IFN-beta production by TLR4-stimulated innate immune cells is negatively regulated by GSK3-beta. J Immunol 181:6797-6802
157. Wang L, Yi T, Kortylewski M et al (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206:1457-1464
158. Wang H, Brown J, Garcia CA et al (2011a) The role of glycogen synthase kinase 3 in regulating IFN-beta-mediated IL-10 production. J Immunol 186:675-684
159. Wang H, Brown J, Gu Z et al (2011b) Convergence of the mammalian target of rapamycin complex 1- and glycogen synthase kinase 3-beta-signaling pathways regulates the innate inflammatory response. J Immunol 186:5217-5226
160. Wang H, Brown J, Martin M (2011c) Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine 53:130-140
161. Wang J, Tang R, Lv M et al (2011d) Defective anchoring of JNK1 in the cytoplasm by MKK7 in Jurkat cells is associated with resistance to Fas-mediated apoptosis. Mol Biol Cell 22:117-127
162. Watcharasit P, Bijur GN, Song L et al (2003) Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem 278:48872-48879
163. Wei W, Jin J, Schlisio S et al (2005) The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8:25-33
164. Welsh GI, Miyamoto S, Price NT et al (1996) T-cell activation leads to rapid stimulation of translation initiation factor eIF2B and inactivation of glycogen synthase kinase-3. J Biol Chem 271:11410-11413
165. Wolf JS, Chen Z, Dong G et al (2001) IL (interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 7:1812-1820
166. Wood JE, Schneider H, Rudd CE (2006) TcR and TcR-CD28 engagement of protein kinase B (PKB/AKT) and glycogen synthase kinase-3 (GSK-3) operates independently of guanine nucleotide exchange factor VAV-1. J Biol Chem 281:32385-32394
167. Woodgett JR (1990) Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9:2431-2438
168. Woodgett JR, Cohen P (1984) Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). Biochim Biophys Acta 788:339-347
169. Wu QM, Yu JP, Tong Q et al (2003) Inhibition of adenovirus-mediated p27kip1 gene on growth of esophageal carcinoma cell strain. World J Gastroenterol 9:2404-2408
170. Yada M, Hatakeyama S, Kamura T et al (2004) Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 23:2116-2125
171. Yan S, Zhou C, Zhang W et al (2008) beta-Catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma. Cancer Lett 271:85-97
172. Yao Z, Fanslow WC, Seldin MF et al (1995) Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3:811-821
173. Yoshida S, Ono M, Shono T et al (1997) Involvement of interleukin- 8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17:4015-4023
174. Zhang HY, Spechler SJ, Souza RF (2009) Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett 275:170-177
175. Zhou XB, Lu N, Zhang W et al (2002) Expression and significance of beta-catenin in esophageal carcinoma. Ai Zheng 21:877-880
176. Zhou Y, Uddin S, Zimmerman T et al (2008) Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk Lymphoma 49:1945-1953